U.S. Hospitality Stock News

Kaiser Aluminum (KALU) just released fourth quarter and full year 2025 results, reporting higher sales and net income than a year earlier. This gives investors fresh numbers to assess the stock’s recent momentum. See our latest analysis for Kaiser Aluminum. The earnings release has come alongside strong recent price action, with a 1-day share price return of 3.70% and a 90-day share price return of 37.29%. The 1-year total shareholder return of 103.76% and 3-year total shareholder return of...

The J. M. Smucker Company recently reported fiscal 2026 third-quarter results showing higher net sales of US$2,339.4 million but a larger net loss of US$724.2 million, alongside slightly narrowed full-year net sales guidance of 3.5% to 4.0% growth and projected diluted EPS in the range of US$1.89 to US$1.39 loss. At the same time, Smucker moved to strengthen its governance and product portfolio by adding two financially experienced independent directors following engagement with Elliott...

If you are wondering whether Jack Henry & Associates is fairly priced at its recent levels, you are not alone. This article focuses squarely on what you are paying versus what you are getting. The stock most recently closed at US$164.20, with a 5.5% return over the last 7 days but declines of 8.4% over 30 days, 7.9% year to date and 6.5% over 1 year, while the 3 year and 5 year returns sit at 3.7% and 15.3% respectively. These mixed returns have kept valuation questions on the table, and...

Dell Technologies recently reported record fourth-quarter and full-year results to January 30, 2026, with revenue of US$33.38 billion for the quarter and US$113.54 billion for the year, alongside higher net income and a quarterly dividend of US$0.63 per share payable on May 1, 2026. The company also expanded its capital return plans with an additional US$10.00 billion share repurchase authorization and highlighted very large growth in AI-optimized server demand supported by a substantial AI...

Pharvaris (NasdaqGS:PHVS) is back in focus after releasing final Phase 2 CHAPTER-1 open-label extension data and detailed RAPIDe-3 results for deucrictibant in hereditary angioedema, underscoring fresh clinical evidence around both prophylactic and on-demand use. See our latest analysis for Pharvaris. The latest deucrictibant data arrives after a powerful run in Pharvaris’ total shareholder return, with an 82.77% 1 year gain and a very large 3 year payoff. The recent 90 day share price return...

In February 2026, Occidental Petroleum launched cash tender offers to buy back multiple series of senior notes and debentures, alongside consent solicitations, while also reporting full-year 2025 results showing broadly stable revenues of about US$22.08 billion and net income of US$2.33 billion, and lifting its quarterly dividend by more than 8% to US$0.26 per share. These moves highlight Occidental’s continued focus on reducing interest-bearing obligations, reinforcing its balance sheet,...

If you are wondering whether MSCI is fairly priced or offering an opportunity right now, it helps to step back and look closely at what the current share price really reflects. The stock last closed at US$573.88, with recent returns of 6.6% over 7 days, a 5.8% decline over 30 days, 1.5% year to date, a 1.2% decline over 1 year, 9.6% over 3 years and 50.4% over 5 years. Taken together, these figures give a mixed picture of recent momentum and risk sentiment. Recent news around MSCI has...

Why Texas Instruments Is On Investors’ Screens Right Now Texas Instruments (TXN) has drawn fresh attention after recent trading left the stock with mixed short term moves but stronger longer term returns, prompting investors to reassess how its current price lines up with recent performance. See our latest analysis for Texas Instruments. At a share price of US$209.82, Texas Instruments has given back some ground in the last month, with a 2.66% 30 day share price decline. However, the 18.20%...

TKO Group Holdings (NYSE:TKO) has agreed multi billion dollar media rights deals for UFC and WWE, including a $7.7b UFC package with Paramount Global that moves events to a subscription only model. The company has partnered with Netflix and ESPN for WWE content distribution and kicked off a $1b share repurchase program. TKO is also launching Zuffa Boxing with international partners and expanding its live events footprint, including premium hospitality management for the 2026 FIFA World...

If you are wondering whether Supernus Pharmaceuticals at around US$55.09 is still offering value after its recent run, you are not alone. The stock has posted returns of 8.7% over the past 7 days, 14.4% over 30 days, 11.4% year to date and 73.6% over 1 year, with longer term returns of 43.5% over 3 years and 116.0% over 5 years. These moves sit against a backdrop of continuing interest in Supernus Pharmaceuticals as a neurology focused drug maker. Investors are paying close attention to how...

ACM Research delivered its first 300mm single wafer cleaning systems to a major foundry in Singapore, marking an entry into Southeast Asia. The company secured new advanced packaging equipment orders from leading global semiconductor customers. ACM Research completed a private share offering intended to support further product development and international expansion. ACM Research (NasdaqGM:ACMR), trading at $57.11 at the last close, has been attracting attention with a very large 3 year...

Why Sirius XM’s new 2032 notes matter for shareholders Sirius XM Holdings (SIRI) has priced an upsized US$1.25b senior notes offering due 2032, using the cash to retire 2026 and 2027 notes, which directly affects its interest costs and future flexibility. See our latest analysis for Sirius XM Holdings. Sirius XM’s refinancing comes as the 30 day share price return of 7.81% and 7 day return of 4.68% contrast with a 1 year total shareholder return decline of 4.01% and a 5 year total shareholder...

If you are trying to work out whether Brightstar Lottery is attractively priced or just a value trap, it helps to start with how the market has treated the stock recently and what that might imply about expectations. The share price last closed at US$13.43, with a 2.9% gain over the past week, a 7.3% decline over the last 30 days, a 12.2% decline year to date, a 4.5% decline over 1 year, and a 32.2% decline over 3 years, set against a 14.8% gain over 5 years. Recent news coverage has focused...

Gold Royalty has upsized and amended its credit facility, securing reduced interest rates. The updated facility is intended to provide greater financial flexibility for future opportunities. Partners operating assets tied to Gold Royalty’s royalties and streams have reported progress on production ramp ups, expansions, drilling, feasibility work, and project milestones. Gold Royalty (NYSEAM:GROY) is drawing investor attention after a series of financing and asset updates, with shares...

Wondering whether Alibaba Group Holding is priced attractively right now, or if the recent excitement is already baked in? This article walks through what the numbers actually say about value. The stock last closed at US$142.56, with a 6.7% decline over the past week, a 15.9% decline over the last month, and returns of 10.8% over 1 year, 67.4% over 3 years, and a 33.8% decline over 5 years. This gives a mixed picture of how the market has been reassessing the company over different time...

Main Street Capital (NYSE:MAIN) reported a record net asset value per share for the 14th consecutive quarter. The company announced an increase to its regular monthly dividend and declared a supplemental dividend. Management highlighted continued strong returns and maintained its focus on shareholder distributions despite market uncertainties. For investors watching income-focused names, NYSE:MAIN now sits at a share price of $57.62, with a value score of 5 and a return of 73.1% over the...

BeOne Medicines (ONC) has drawn investor attention after its rebrand from BeiGene, Ltd. to BeOne Medicines AG in May 2025. The change highlights a broad oncology portfolio across commercial, clinical, and preclinical cancer therapies. See our latest analysis for BeOne Medicines. After the rebrand, BeOne Medicines’ share price has been under pressure in the short term, with a 7 day share price return of a 15.18% decline and a 30 day share price return of a 7.64% decline. Its 1 year total...

Procter & Gamble (PG) is back in the spotlight after quarterly results that met revenue expectations, exceeded EBITDA forecasts, and kept full year guidance intact, alongside fresh product launches in its key laundry brands. See our latest analysis for Procter & Gamble. At a share price of $163.51, Procter & Gamble has seen a 7.74% 1 month share price return and a 12.10% 3 month share price return, while its 1 year total shareholder return of 4.32% decline contrasts with a 45.70% gain over...

In recent months, BellRing Brands has reinforced its position in the protein-based nutrition market, with its Premier Protein and Dymatize lines supporting solid revenue and profit growth alongside resilient net margins. This performance highlights how premium branding, focused product specialization, and a broad lineup are helping the company strengthen its competitive position in a crowded category. We’ll now examine how this strong momentum in protein-based nutrition, supported by...

CoStar Group reported fourth-quarter 2025 revenue of US$900 million, up from US$709 million a year earlier, while net income declined to US$47 million from US$60 million, and it concurrently rolled out Homes AI, a Microsoft Azure OpenAI-powered, conversational home-search experience on Homes.com. Amid mixed analyst reactions to recent earnings and guidance, President and CEO Andrew Florance’s purchase of 55,720 shares stands out as a rare insider buy after a year dominated by insider...

Morgan Stanley’s recent call naming Citigroup (C) as its top pick has renewed attention on the bank’s stock, as investors weigh ongoing transformation efforts, cost discipline, and the upcoming May 7 investor day. See our latest analysis for Citigroup. Citigroup’s recent 1-day share price return of 1.14% and 90-day share price return of 8% come after inflation driven credit risk worries briefly knocked sentiment. The 1-year total shareholder return of 48.18% shows that momentum has been...

Imperial Petroleum Inc. has announced it will release its fourth-quarter and full-year 2025 results on 6 March 2026, followed by a management conference call, and is moving ahead with plans to grow its fleet from 20 to 26 vessels totaling about 1.5 million deadweight tons. This combination of upcoming financial disclosure and substantial fleet expansion highlights a meaningful shift in the company’s operational scale and future capacity profile. With Imperial Petroleum preparing to expand...

If you are wondering whether Aramark is fairly priced today or if there is still room for value, this article walks through what the numbers are actually saying about the stock. The share price recently closed at US$41.26, with returns of 1.7% over 7 days, 7.2% over 30 days, 12.8% year to date and 15.9% over 1 year, plus 3 year and 5 year returns of 51.7% and 43.7% respectively. Recent news coverage around Aramark has largely focused on its position in the outsourced services and facilities...

In late February 2026, Kymera Therapeutics reported a wider full-year 2025 net loss of US$311.35 million and loss per share of US$3.69, while simultaneously filing a US$392.14 million shelf registration linked to an ESOP offering and a US$500 million at-the-market equity program. Alongside these financings, Kymera advanced its oral STAT6 and IRF5 degrader programs, added veteran developer Neil Graham as Chief Development Officer, and maintained strong backing from major pharma collaborators...